Objective   To evaluate the effect of neoadjuvant chemotherapy on the prognosis of muscle-invasive bladder cancer.    Methods   Published prospective randomized controlled trials (RCT) on neoadjuvant chemotherapy for muscle-invasive bladder cancer were searched and screened in Pubmed

EMBASE

CBMdisc

Cochrane library and Wanfang databases under preset standards. The data from eligible studies were pooled through Meta-analysis.    Results   Totally 12 trials including 3 286 patients were eligible to the criteria (1 636 in study group and 1 650 in control group).The odds radio of all trails tended to favour neoadjuvant chemotherapy (OR=0.85

95% CI 0.73 to 0.98

P=0.03). Platinum-based combination chemotherapy showed a significant reduction in risk of death（OR=0.79

95% CI=0.67 to 0.92

P=0.0004)

but there was no evidence to support the use of single-agent platinum.     Conclusions   Neoadjuvant chemotherapy especially platinum-based combination chemotherapy is beneficial to muscle-invasive bladder cancer patients.